JPMorgan and Morgan Stanley enhance buybacks and dividends, even though Citigroup and BofA get more compact techniques

Important Points

JPMorgan claimed it was increasing its quarterly dividend 8.7% to $1.25 for every share and that it approved a new $30 billion share repurchase plan.
Morgan Stanley mentioned it was boosting its dividend 8.8% to 92.5 cents per share and authorized a $20 billion repurchase system.
Citigroup said it was boosting its dividend 5.7% to 56 cents per share and that it would “keep on to assess share repurchases” on a quarterly foundation.
Financial institution of America explained it was escalating its dividend 8% to 26 cents for every share its launch made no mention of share repurchases.

Source

Finance

Stocks making the biggest moves midday: KKR, Blackstone, CrowdStrike, International Paper & more

February 23, 2026

Check out the companies making the biggest moves midday: Financials — The financials sector of the S & P 500 slid more than 3% in midday trading, the worst performer in the broad market. Alternative asset managers KKR and Blackstone slid roughly 9% and 7%, respectively, after activist hedge fund Saba Capital Management and Cox […]

Bitcoin falls to nearly ,000 as 2026 crypto woes continue

Finance

Bitcoin falls to nearly $64,000 as 2026 crypto woes continue

February 23, 2026

Key Points Bitcoin traded as low as $64,830 early Monday. The token slid nearly 5% from Sunday to Monday, hitting at one point its lowest level in more than two weeks. Investors are rotating out of risk-on trades like bitcoin and turning to gold as confusion over Trump’s latest tariffs has spread and a war […]

Finance

Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino’s Pizza and more

February 23, 2026

Check out the companies making headlines before the bell. Arcellx — The biotech stock surged 78% after Gilead Sciences said Monday it agreed to acquire Arcellx for $7.8 billion, offering $115 per share in cash at closing and one contingent value right of $5 per share. Arcellx focuses on immunotherapies for patients with cancer and […]